Descriptor English: | Neostigmine | ||||||
Descriptor Spanish: |
Neostigmina
| ||||||
Descriptor Portuguese: | Neostigmina | ||||||
Descriptor French: | Néostigmine | ||||||
Entry term(s): |
Bromide, Neostigmine Methylsulfate, Neostigmine Neostigmine Bromide Neostigmine Methylsulfate Polstigmine Proserine Prostigmin Prostigmine Prozerin Synstigmin Syntostigmine |
||||||
Tree number(s): |
D02.092.877.674.666 D02.675.276.602 |
||||||
RDF Unique Identifier: | https://id.nlm.nih.gov/mesh/D009388 | ||||||
Scope note: | A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier. |
||||||
Allowable Qualifiers: |
AA analogs & derivatives AD administration & dosage AE adverse effects AG agonists AI antagonists & inhibitors AN analysis BL blood CF cerebrospinal fluid CH chemistry CL classification CS chemical synthesis EC economics HI history IM immunology IP isolation & purification ME metabolism PD pharmacology PK pharmacokinetics PO poisoning RE radiation effects SD supply & distribution ST standards TO toxicity TU therapeutic use UR urine |
||||||
Pharm Action: |
Cholinesterase Inhibitors Parasympathomimetics |
||||||
Registry Number: | 3982TWQ96G | ||||||
CAS Type 1 Name: | Benzenaminium, 3-(((dimethylamino)carbonyl)oxy)-N,N,N-trimethyl- | ||||||
DeCS ID: | 9581 | ||||||
Unique ID: | D009388 | ||||||
NLM Classification: | QV 124 | ||||||
Documents indexed in the Virtual Health Library (VHL): | Click here to access the VHL documents | ||||||
Date Established: | 1966/01/01 | ||||||
Date of Entry: | 1999/01/01 | ||||||
Revision Date: | 2013/07/08 |
-
-
CHEMICALS AND DRUGS
Organic Chemicals [D02]Organic Chemicals -
CHEMICALS AND DRUGS
Organic Chemicals [D02]Organic Chemicals
|
Neostigmine
- Preferred
Polstigmine
- Narrower
Neostigmine Bromide
- Narrower
Syntostigmine
- Narrower
Neostigmine Methylsulfate
- Narrower
Prostigmine
- Narrower
Concept UI |
M0014615 |
Scope note | A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier. |
Preferred term | Neostigmine |
Entry term(s) |
Proserine Prozerin Synstigmin |
Concept UI |
M0014617 |
Preferred term | Polstigmine |
Concept UI |
M0351163 |
Preferred term | Neostigmine Bromide |
Entry term(s) |
Bromide, Neostigmine |
Concept UI |
M0014618 |
Preferred term | Syntostigmine |
Concept UI |
M0014616 |
Preferred term | Neostigmine Methylsulfate |
Entry term(s) |
Methylsulfate, Neostigmine |
Concept UI |
M0014619 |
Preferred term | Prostigmine |
Entry term(s) |
Prostigmin |
We want your feedback on the new DeCS / MeSH website
We invite you to complete a survey that will take no more than 3 minutes.
Go to survey